Edition:
United States

Flexion Therapeutics Inc (FLXN.OQ)

FLXN.OQ on NASDAQ Stock Exchange Global Market

26.97USD
29 Mar 2017
Change (% chg)

-- (--)
Prev Close
$26.97
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
146,637
52-wk High
$29.41
52-wk Low
$8.23

Latest Key Developments (Source: Significant Developments)

Flexion reports year-end 2016 financial results
Thursday, 9 Mar 2017 04:01pm EST 

Flexion Therapeutics Inc : Flexion reports year-end 2016 financial results . Frederick Driscoll, chief financial officer, intends to retire effective March 31, 2017 . Driscoll will continue with company in an advisory capacity until his successor has been named .Commercialization plans on target for potential Q4 launch of zilretta.  Full Article

Flexion Therapeutics announces NDA for Zilretta accepted by U.S. FDA
Tuesday, 7 Feb 2017 07:30am EST 

Flexion Therapeutics Inc : Flexion Therapeutics announces new drug application for Zilretta™ (fx006) accepted by U.S. Food and Drug Administration .Flexion Therapeutics Inc - agency has established a user fee goal date under prescription drug user fee act (PDUFA) of October 6, 2017.  Full Article

Flexion Therapeutics announces pricing of public offering of common stock
Wednesday, 16 Nov 2016 09:00am EST 

Flexion Therapeutics Inc : Says public offering of 3.60 million common shares priced at $18.00 per share .Flexion Therapeutics announces pricing of public offering of common stock.  Full Article

Flexion Therapeutics reports Q2 2016 financial results
Wednesday, 3 Aug 2016 04:01pm EDT 

Flexion Therapeutics : Reports Second Quarter 2016 financial results . Reported a net loss of $14.2 million for Q2 of 2016, compared to a net loss of $12.4 million for Q2 of 2015 .Following positive guidance from U.S. FDA planned New Drug Application (NDA) submission on track for Q4 of 2016.  Full Article

Flexion Therapeutics announces pricing of public offering of common stock
Wednesday, 8 Jun 2016 09:00am EDT 

Flexion Therapeutics Inc : Flexion Therapeutics announces pricing of public offering of common stock .Says public offering of 5.50 mln common shares priced at $14.00/shr.  Full Article

Flexion Therapeutics expects to incur "significant losses for foreseeable future"
Tuesday, 7 Jun 2016 04:54pm EDT 

Flexion Therapeutics Inc : Anticipate that we will continue to incur significant losses for foreseeable future .As of March 31, 2016, had an accumulated deficit of $156.6 million.  Full Article

Flexion Therapeutics announces proposed public offering of stock
Tuesday, 7 Jun 2016 04:05pm EDT 

Flexion Therapeutics Inc: Flexion therapeutics announces proposed public offering of common stock .Commenced an underwritten public offering, to issue and sell approximately $60.0 million of shares.  Full Article

Flexion Therapeutics qtrly loss per share $0.78
Thursday, 12 May 2016 04:01pm EDT 

Flexion Therapeutics Reports First : Qtrly loss per share $0.78 .Quarter 2016 financial results.  Full Article

Flexion Therapeutics, Inc reports top-line data from pivotal Phase 2B clinical trial for FX006
Tuesday, 8 Sep 2015 04:01pm EDT 

Flexion Therapeutics, Inc:Reports top-line data from pivotal phase 2b clinical trial for fx006.Says fx006 provides substantial and persistent pain relief compared to placebo.Fx006 well-tolerated with safety profile comparable to placebo.Says primary endpoint of the trial, superiority in pain relief at 12 weeks, did not reach statistical significance.  Full Article

Flexion Therapeutics granted fast track status by the FDA for FX006
Tuesday, 1 Sep 2015 04:00pm EDT 

Flexion Therapeutics:Says that U.S. Food and Drug Administration has granted Fast Track designation for FX006, Flexion's late-stage, lead drug candidate that is designed as a treatment for the more than four million U.S. patients receiving intra-articular (IA) injections for osteoarthritis (OA) of the knee.Flexion is currently studying FX006 in a Phase 2b pivotal trial, with top-line data expected to be announced soon, as well as in a Phase 3 clinical trial for which it expects to share data in the first quarter of 2016.  Full Article

More From Around the Web

BRIEF-Flexion reports year-end 2016 financial results

* Frederick Driscoll, chief financial officer, intends to retire effective March 31, 2017